2025
Update on Acute Tubulointerstitial Nephritis: Clinical Features, Immunologic Insights, and Diagnostic and Treatment Approaches
Sahutoglu T, Perazella M. Update on Acute Tubulointerstitial Nephritis: Clinical Features, Immunologic Insights, and Diagnostic and Treatment Approaches. Kidney International Reports 2025, 10: 1643-1656. DOI: 10.1016/j.ekir.2025.03.050.Peer-Reviewed Original ResearchAcute tubulointerstitial nephritisAcute kidney injuryC-reactive proteinAcute kidney diseaseTubulointerstitial nephritisType IV hypersensitivity mechanismKidney diseaseAcute kidney injury etiologyTh2-mediated immune responsesSerum C-reactive proteinTriggered by medicationsTumor necrosis factor (TNF)-aInterleukin (IL)-9Urinary retinol-binding proteinT helper (Th)1T cell polarizationIrreversible kidney damageInflammatory endotypesImprove patient outcomesPrompt diagnosisKidney biopsyT cellsClinical featuresDiagnostic challengeImmune heterogeneity
2022
Prognosis of hospitalized patients with cirrhosis and acute kidney disease
Wong F, Garcia‐Tsao G, Reddy KR, O'Leary JG, Kamath PS, Tandon P, Lai JC, Vargas HE, Biggins SW, Fallon MB, Thuluvath PJ, Maliakkal BJ, Subramanian R, Thacker L, Bajaj JS. Prognosis of hospitalized patients with cirrhosis and acute kidney disease. Liver International 2022, 42: 896-904. PMID: 35023264, PMCID: PMC11075740, DOI: 10.1111/liv.15154.Peer-Reviewed Original ResearchConceptsAcute kidney diseaseStage 1 AKIAKD patientsPeak ScrAKI patientsCirrhotic patientsKidney diseaseSecond infectionEnd-stage liver diseaseDecompensated cirrhotic patientsHigher hospital admissionsWorse renal dysfunctionNormal renal functionGlomerular filtration rateNorth American ConsortiumBaseline SCrRenal dysfunctionPrompt treatmentRenal functionSerum creatinineHospital admissionClinical outcomesLiver diseasePredictive factorsFiltration rate
2020
Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference
Levey AS, Eckardt KU, Dorman NM, Christiansen SL, Hoorn EJ, Ingelfinger JR, Inker LA, Levin A, Mehrotra R, Palevsky PM, Perazella MA, Tong A, Allison SJ, Bockenhauer D, Briggs JP, Bromberg JS, Davenport A, Feldman HI, Fouque D, Gansevoort RT, Gill JS, Greene EL, Hemmelgarn BR, Kretzler M, Lambie M, Lane PH, Laycock J, Leventhal SE, Mittelman M, Morrissey P, Ostermann M, Rees L, Ronco P, Schaefer F, St Clair Russell J, Vinck C, Walsh SB, Weiner DE, Cheung M, Jadoul M, Winkelmayer WC. Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. Kidney International 2020, 97: 1117-1129. PMID: 32409237, DOI: 10.1016/j.kint.2020.02.010.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseGlomerular filtration rateKidney diseaseKidney functionKDIGO definitionConsensus conferenceSeverity of CKDEnd-stage kidney diseaseAcute kidney diseaseAbsence of symptomsGlobal Outcomes (KDIGO) Consensus ConferenceKDIGO guidelinesKidney injuryKidney failureKidney measuresFiltration rateWorldwide burdenGlobal outcomeKidney structureDiseaseHealth communitySeverityFollowing recommendationsMore effective communication
2019
Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis
Moledina DG, Wilson FP, Pober JS, Perazella MA, Singh N, Luciano RL, Obeid W, Lin H, Kuperman M, Moeckel GW, Kashgarian M, Cantley LG, Parikh CR. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight 2019, 4: e127456. PMID: 31092735, PMCID: PMC6542610, DOI: 10.1172/jci.insight.127456.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisAcute kidney diseasePrebiopsy diagnosisKidney biopsyKidney diseaseIL-9AIN diagnosisUrine TNFInterstitial nephritisSpecific T cell subsetsAcute tubular injuryDiabetic kidney diseaseIL-9 levelsTNF-α levelsT cell subsetsAddition of biomarkersPlasma cytokinesCytokine levelsTubular injuryHighest quartileMultivariable analysisCell subsetsUrinary TNFBlood eosinophilsGlomerular disease
2018
Kidney Biopsy–Related Complications in Hospitalized Patients with Acute Kidney Disease
Moledina DG, Luciano RL, Kukova L, Chan L, Saha A, Nadkarni G, Alfano S, Wilson FP, Perazella MA, Parikh CR. Kidney Biopsy–Related Complications in Hospitalized Patients with Acute Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2018, 13: 1633-1640. PMID: 30348813, PMCID: PMC6237071, DOI: 10.2215/cjn.04910418.Peer-Reviewed Original ResearchConceptsAcute kidney diseaseBiopsy-related complicationsLow platelet countHospitalized patientsNonhospitalized patientsKidney biopsyKidney diseasePlatelet countHigher BUNFemale sexRisk factorsLarge-sized hematomaStage 1 AKIRate of complicationsProcedure-related bleedingLarger needle gaugeAbdominal ultrasonographyBiopsy cohortBlood transfusionAngiographic interventionMultivariable analysisPostbiopsy complicationsMultivariable associationsHigh riskTransfusionThe adverse kidney effects of cancer immunotherapies
Saly D, Perazella M. The adverse kidney effects of cancer immunotherapies. Journal Of Onco-Nephrology 2018, 2: 56-68. DOI: 10.1177/2399369318808806.Peer-Reviewed Original ResearchChronic kidney diseaseKidney diseaseCancer immunotherapyInterleukin-2High-dose interleukin-2Chimeric antigen receptor T cellsAntigen receptor T cellsMore effective treatment optionsAdverse kidney effectsImmune checkpoint inhibitorsAcute kidney diseaseEffective treatment optionReceptor T cellsCase-based reviewCancer therapyGroup of drugsNew cancer immunotherapiesCancer treatment armamentariumConventional chemotherapeutic drugsList of cancersOlder immunotherapiesCheckpoint inhibitorsTreatment armamentariumNew immunotherapiesTreatment optionsProgressive kidney disease may not alter the association of hyponatremia with mortality
Golestaneh L, Neugarten J, Kaskel F, McGinn A. Progressive kidney disease may not alter the association of hyponatremia with mortality. Clinical And Experimental Nephrology 2018, 22: 889-897. PMID: 29396621, DOI: 10.1007/s10157-018-1536-8.Peer-Reviewed Original ResearchConceptsAcute kidney injuryChronic kidney diseaseAcute kidney injury cohortAssociated with mortalityKidney diseaseHazard ratioProgressive stages of CKDMonths of follow-upStages of chronic kidney diseasePrevalence of chronic kidney diseaseChronic kidney disease cohortAssociation of hyponatremiaKidney disease stageStages of kidney diseaseCox regression modelsAcute kidney diseaseProgressive kidney diseaseAdvanced kidney diseaseHyponatremic patientsLoss of statistical significancePrognostic markerElectrolyte disordersKidney injuryCharlson scoreHyponatremia
2008
NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment
Knopp EA, Cowper SE. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis: Early Recognition and Treatment. Seminars In Dialysis 2008, 21: 123-128. PMID: 18226008, DOI: 10.1111/j.1525-139x.2007.00399.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNephrogenic systemic fibrosisGadolinium-containing contrast agentsEarly recognitionSystemic fibrosisAcute kidney diseaseSignificant risk factorsInvolved extremityRenal dysfunctionRenal insufficiencyExtracorporeal photopheresisRenal functionMedical therapyMuscle weaknessKidney diseaseRisk factorsDistressing diseaseEarly treatmentPhysical therapyEffective treatmentEarly symptomsEarly signsPatientsBeneficial effectsFibrosisTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply